Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N.

Kidney Int. 2005 Jun;67(6):2346-53.

2.

Pure red-cell aplasia "epidemic"--mystery completely revealed?

Locatelli F, Del Vecchio L, Pozzoni P.

Perit Dial Int. 2007 Jun;27 Suppl 2:S303-7. Review.

3.

Epoetin-associated pure red cell aplasia: past, present, and future considerations.

McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL.

Transfusion. 2008 Aug;48(8):1754-62. doi: 10.1111/j.1537-2995.2008.01749.x. Epub 2008 May 14. Review.

4.

[Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].

Opatrný K Jr.

Cas Lek Cesk. 2003;142(12):741-5. Review. Czech.

PMID:
14746223
5.

Importance of biologic follow-ons: experience with EPO.

Casadevall N, Rossert J.

Best Pract Res Clin Haematol. 2005;18(3):381-7. Review.

PMID:
15792912
6.

Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.

Macdougall IC.

Curr Med Res Opin. 2004 Jan;20(1):83-6. Review. Erratum in: Curr Med Res Opin. 2004 Apr;20(4):576.

PMID:
14741076
7.

Epoetins: differences and their relevance to immunogenicity.

Haselbeck A.

Curr Med Res Opin. 2003;19(5):430-2. Review.

PMID:
13678480
8.
9.

Factors influencing the immunogenicity of therapeutic proteins.

Schellekens H.

Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi3-9. Review.

10.

Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?

Macdougall IC.

Nephrol Dial Transplant. 2005 Sep;20 Suppl 8:viii18-21. Review.

11.

[Possible complications of erythropoietin therapy in patients with chronic renal failure].

Pljesa S.

Med Pregl. 2004 May-Jun;57(5-6):254-7. Review. Serbian.

PMID:
15503795
12.

Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.

Macdougall IC.

Nephrol Dial Transplant. 2005 May;20 Suppl 4:iv9-15. Review.

13.

Pure red cell aplasia secondary to treatment with erythropoietin.

Locatelli F, Del Vecchio L.

J Nephrol. 2003 Jul-Aug;16(4):461-6. Review.

PMID:
14696747
14.

Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge.

Smalling R, Foote M, Molineux G, Swanson SJ, Elliott S.

Biotechnol Annu Rev. 2004;10:237-50. Review.

PMID:
15504708
15.

[Pure red cell aplasia (PRCA) induced by anti-EPO antibodies: epidemiology, diagnosis and treatment].

Janda K, Kraśniak A, Krzanowski M, Sułowicz W.

Przegl Lek. 2010;67(3):187-91. Review. Polish.

PMID:
20687383
16.

Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

Casadevall N.

Nephrol Dial Transplant. 2003 Nov;18 Suppl 8:viii37-41. Review.

17.

Immunologic mechanisms of EPO-associated pure red cell aplasia.

Schellekens H.

Best Pract Res Clin Haematol. 2005;18(3):473-80. Review.

PMID:
15792922
18.

Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group.

Evens AM, Bennett CL, Luminari S.

Best Pract Res Clin Haematol. 2005;18(3):481-9. Review.

PMID:
15792923
19.

[Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin].

Grzegorzewska AE, Sucharzewska-Tomczak M.

Pol Merkur Lekarski. 2004 Oct;17(100):407-9. Review. Polish.

PMID:
15690716
20.
Items per page

Supplemental Content

Write to the Help Desk